We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+53.69%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$824M
AUM Growth
+$164M
Cap. Flow
-$47.9M
Cap. Flow %
-5.82%
Top 10 Hldgs %
67.4%
Holding
35
New
8
Increased
2
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
PALI icon
Palisade Bio
PALI
+$18.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.8M
3
ALMS
Alumis Inc
ALMS
+$17.7M
4
LXEO icon
Lexeo Therapeutics
LXEO
+$15.7M
5
BIOA
BioAge Labs
BIOA
+$14.2M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$62.1M
2
MRUS
Merus
MRUS
+$29M
3
APLS
Apellis Pharmaceuticals
APLS
+$20.4M
4
COGT icon
Cogent Biosciences
COGT
+$14.7M
5
NUVB icon
Nuvation Bio
NUVB
+$9.74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11.7B
$102M 12.38%
756,000
-569,000
-43% -$62.1M
DNTH icon
2
Dianthus Therapeutics
DNTH
$5.61B
$99.6M 12.09%
2,416,667
– –
COGT icon
3
Cogent Biosciences
COGT
$6.63B
$83.5M 10.13%
2,350,000
-524,111
-18% -$14.7M
TSHA icon
4
Taysha Gene Therapies
TSHA
$1.65B
$48.7M 5.92%
8,859,911
-207,589
-2% -$1.01M
GOSS icon
5
Gossamer Bio
GOSS
$72.8M
$43.1M 5.24%
13,915,371
-3,134,629
-18% -$8.94M
KYMR icon
6
Kymera Therapeutics
KYMR
$9.33B
$41.6M 5.05%
535,000
+175,000
+49% +$11.8M
AVBP icon
7
ArriVent BioPharma
AVBP
$1.42B
$39.7M 4.81%
1,971,054
– –
TRVI icon
8
Trevi Therapeutics
TRVI
$2.49B
$35.2M 4.28%
2,815,000
– –
OCUL icon
9
Ocular Therapeutix
OCUL
$1.93B
$31.9M 3.87%
2,623,600
-400
-0% -$4.86K
DFTX
10
Definium Therapeutics
DFTX
$5.86B
$29.9M 3.63%
2,230,000
+100,000
+5% +$1.24M
CGON icon
11
CALL
CG Oncology
CGON
$6.32B
$24.9M 3.02%
+600,000
New +$24.8M
ALMS
12
Alumis Inc
ALMS
$3.63B
$24.7M 3%
+2,530,700
New +$17.7M
PALI icon
13
Palisade Bio
PALI
$341M
$22.5M 2.73%
+9,567,898
New +$18.4M
CDTX
14
DELISTED
Cidara Therapeutics
CDTX
$22.1M 2.68%
100,000
– –
BIOA
15
BioAge Labs
BIOA
$997M
$21.1M 2.57%
+1,598,000
New +$14.2M
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$20.6M 2.5%
1,273,333
– –
RAPT
17
DELISTED
RAPT Therapeutics
RAPT
$19.4M 2.36%
+574,000
New +$17.8M
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$18.8M 2.28%
750,000
-80,000
-10% -$2.03M
PHVS icon
19
Pharvaris
PHVS
$2.4B
$18.6M 2.26%
671,465
-51,130
-7% -$1.23M
LXEO icon
20
Lexeo Therapeutics
LXEO
$360M
$17.1M 2.08%
+1,725,000
New +$15.7M
BBOT
21
BridgeBio Oncology
BBOT
$678M
$13.1M 1.59%
1,043,110
– –
DBVT
22
DBV Technologies
DBVT
$850M
$11M 1.34%
574,200
-443,821
-44% -$6.93M
EVMN
23
Evommune Inc
EVMN
$410M
$8.56M 1.04%
+500,000
New +$9.39M
DTIL icon
24
Precision BioSciences
DTIL
$193M
$7.98M 0.97%
+1,917,995
New +$10.9M
CRBP icon
25
Corbus Pharmaceuticals
CRBP
$167M
$7.77M 0.94%
955,000
-160,000
-14% -$1.97M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Octagon Capital Advisors held 35 positions worth $824M, up 25% from $660M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Octagon Capital Advisors withdrew a net $47.9M in Q4 2025, closing 8 positions and reducing 9 holdings. Its most notable exit was Merus, an estimated $29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

Against the trend, Octagon Capital Advisors opened a new position in Palisade Bio worth $22.5M.

  • Octagon Capital Advisors's largest Q4 2025 buy was Palisade Bio: 9,567,898 shares worth $22.5M.
  • Octagon Capital Advisors added most to Kymera Therapeutics in Q4 2025, an estimated $11.8M increase.
  • Octagon Capital Advisors's biggest Q4 2025 reduction was Abivax, cutting an estimated $62.1M.
  • Octagon Capital Advisors fully exited Merus in Q4 2025, selling an estimated $29M.
  • Octagon Capital Advisors's ten largest holdings make up 67% of its $824M portfolio in Q4 2025.
  • Octagon Capital Advisors opened 8 new positions and closed 8 in Q4 2025.
  • Octagon Capital Advisors's portfolio value rose 25% quarter-over-quarter to $824M.

Based on Octagon Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.